https://pharmadog.xyz/news/404084 pharmadog en 2026-09-14T13:07:51.000Z STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more https://pharmadog.xyz/news/404104 pharmadog en 2026-09-14T13:00:00.000Z Scholar Rock SMA drug approved by FDA https://pharmadog.xyz/news/403995 pharmadog en 2026-09-14T12:47:07.000Z AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market https://pharmadog.xyz/news/403996 pharmadog en 2026-09-14T12:17:38.000Z Scholar Rock secures first FDA approval for muscle-targeting rare disease drug https://pharmadog.xyz/news/403803 pharmadog en 2026-09-14T11:54:13.000Z Novo Nordisk rebrands as 'Novo' and launches new culture strategy after recent setbacks https://pharmadog.xyz/news/403867 pharmadog en 2026-09-14T11:49:09.000Z Third measles-related death reported in Pennsylvania amid ongoing outbreak https://pharmadog.xyz/news/403804 pharmadog en 2026-09-14T11:29:31.000Z Scholar Rock receives FDA approval for apitegromab (Isembyld) to treat spinal muscular atrophy https://pharmadog.xyz/news/403805 pharmadog en 2026-09-14T11:21:38.000Z AstraZeneca's Etcamah fails late-stage trial for early-stage breast cancer use https://pharmadog.xyz/news/403695 pharmadog en 2026-09-14T11:00:08.000Z Definium Therapeutics reports positive Phase 3 results for oral LSD anxiety drug DT120 https://pharmadog.xyz/news/403739 pharmadog en 2026-09-14T11:00:00.000Z Definium’s LSD therapy cuts anxiety scores in second late-stage trial https://pharmadog.xyz/news/403463 pharmadog en 2026-09-14T08:58:48.000Z Novo Nordisk rebrands as "Novo" to signal renewed focus amid slipping market share https://pharmadog.xyz/news/403466 pharmadog en 2026-09-14T08:30:00.000Z Hospital leaders say GOP's $50 billion rural health fund falls far short of Medicaid cuts https://pharmadog.xyz/news/403464 pharmadog en 2026-09-14T08:30:00.000Z Football fan wrestles with love for the game amid rising CTE concerns https://pharmadog.xyz/news/403465 pharmadog en 2026-09-14T08:30:00.000Z Opinion: Restoring public trust in science requires humility and collaboration, not just better messaging https://pharmadog.xyz/news/402803 pharmadog en 2026-09-14T07:00:00.000Z Cyclic peptide drugs gain traction as AI and hybrid synthesis aim to overcome manufacturing hurdles https://pharmadog.xyz/news/403779 pharmadog en 2026-09-14T06:55:00.000Z Novo rebrands, drops 'Nordisk' to become simply 'Novo' in market push https://pharmadog.xyz/news/403672 pharmadog en 2026-09-14T05:28:00.000Z Cellectis drops its allogeneic CAR-T candidates lasme-cel and eti-cel amid rising competition from in-vivo therapies https://pharmadog.xyz/news/403502 pharmadog en 2026-09-14T05:11:00.000Z Roche-MediLink’s B7-H3 ADC meets primary endpoint in phase 3 SCLC trial, median survival 13.3 months https://pharmadog.xyz/news/402804 pharmadog en 2026-09-14T05:00:00.000Z Sino Biological launches site-specific labeled proteins to aid cell surface research https://pharmadog.xyz/news/402805 pharmadog en 2026-09-14T04:20:00.000Z Public backing fuels FDA hearing on psychedelic therapies and potential COMP360 approval https://pharmadog.xyz/news/402655 pharmadog en 2026-09-14T04:01:00.000Z Merck and Moderna’s melanoma vaccine success spurs five rivals to chase personalized cancer vaccine breakthrough https://pharmadog.xyz/news/402656 pharmadog en 2026-09-14T04:00:00.000Z FDA approves Moderna’s mRNA flu vaccine as company reports positive Phase 3 cancer vaccine results https://pharmadog.xyz/news/401804 pharmadog en 2026-09-13T22:30:00.000Z Analysis says secret Trump pharma deals could cut projected Medicare savings from MFN pricing by up to 80% https://pharmadog.xyz/news/403946 pharmadog en 2026-09-13T11:53:00.000Z J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg https://pharmadog.xyz/news/400006 pharmadog en 2026-09-13T08:05:00.000Z GE HealthCare eyes $1 billion purchase of radiopharmaceutical developer Sofie Biosciences https://pharmadog.xyz/news/398267 pharmadog en 2026-09-13T01:46:49.000Z Akeso and Summit report survival advantage for PD-1xVEGF combo over Keytruda